Management of patients with inflammatory bowel disease and spondyloarthritis

Lieven Pouillon, Peter Bossuyt, Joke Vanderstukken, David Moulin, Patrick Netter, Silvio Danese, Jean Yves Jouzeau, Damien Loeuille, Laurent Peyrin-Biroulet

Research output: Contribution to journalReview articlepeer-review


Introduction: More than half of the patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM). The most common EIM in patients with IBD is spondyloarthritis (SpA). Microscopic intestinal inflammation is documented in almost 50% of the patients with SpA. Areas covered: We give an overview of the classification, the epidemiology and the diagnosis of IBD and SpA. The treatment goals, the pharmacologic management options and the available treatment guidelines in IBD patients with SpA are discussed. Expert commentary: The coexistence of IBD and SpA generates challenges and opportunities for both the gastroenterologist and the rheumatologist. The potential of drugs with a gut-specific mode of action in the treatment of IBD-related arthritis warrants further exploration.

Original languageEnglish
Pages (from-to)1363-1374
Number of pages12
JournalExpert Review of Clinical Pharmacology
Issue number12
Publication statusPublished - Dec 2 2017


  • Crohn’s disease
  • inflammatory bowel disease
  • spondyloarthritis
  • treat-to-target
  • ulcerative colitis

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)


Dive into the research topics of 'Management of patients with inflammatory bowel disease and spondyloarthritis'. Together they form a unique fingerprint.

Cite this